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Abstract 
Dengue viruses (DV) represent a significant global health burden, with up to 400 million 
infections every year and around 500,000 infected individuals developing life-
threatening disease. In spite of attempts in developing vaccine candidates and anti-viral 
drugs, there is currently a lack of approved therapeutics for the treatment of DV 
infection. We have previously reported the identification of ST-148, a small molecule 
inhibitor exhibiting a broad and potent antiviral activity against DV in vitro and in vivo. In 
the present study, we investigated the mode-of-action of this promising compound by 
using a combination of biochemical, virological and imaging-based techniques. We 
confirmed that ST-148 targets the capsid protein and obtained evidence of a bi-modal 
antiviral activity affecting both assembly/release and entry of infectious DV particles. 
Importantly, by using a robust bioluminescence resonance energy transfer-based assay 
we observed a ST-148-dependent increase of capsid self-interaction. These results 
were corroborated by molecular modeling studies that also revealed a plausible model 
for compound binding to capsid protein and inhibition by a distinct resistance mutation. 
These results suggest that ST-148-enhanced capsid protein self-interaction perturbs 
assembly and disassembly of DV nucleocapsids probably by inducing structural rigidity. 
Thus, as previously reported for other enveloped viruses, stabilization of capsid protein 
structure is an attractive therapeutic concept also applicable for flaviviruses. 
͵ 
Importance 
Dengue viruses (DV) are arthropod-borne viruses representing a significant global 
health burden. They infect up to 400 million people and are endemic in subtropical and 
tropical areas of the world. Currently, there are neither vaccines nor approved 
therapeutics for the prophylaxis or the treatment of DV infections, respectively. This
study reports the characterization of the mode-of-action of ST-148, a small-molecule 
capsid inhibitor with potent antiviral activity against all DV serotypes. Our results 
demonstrate that ST-148 stabilizes capsid protein self-interaction, thereby likely 
perturbing assembly and disassembly of viral nucleocapsids by inducing structural 
rigidity. This, in turn, might interfere with the release of viral RNA from incoming 
nucleocapsids (uncoating) as well as assembly of progeny virus particles. As 
previously reported for other enveloped viruses, we propose capsid as a novel tractable 
target for flavivirus inhibitors. 
Ͷ 
Introduction 
Dengue virus (DV) belongs to the genus Flavivirus, a large group of emerging 
pathogens capable of causing severe human diseases. Among these, DV represents
the most prevalent mosquito-borne human-pathogenic virus worldwide, comprising 4 
serotypes that are mainly transmitted by infected Aedes mosquitoes during a blood 
meal. DV infections can lead to a wide range of clinical manifestations, ranging from 
asymptomatic infections to life-threatening dengue hemorrhagic fever and shock 
syndrome. A recent study estimated around 390 million DV infections each year, 
resulting in approximately 100 million symptomatic cases and around 25,000 deaths (1). 
Despite intense efforts and growing public interest, no licensed antiviral drug against DV 
infection is available, and the most advanced DV vaccine candidate did not meet 
expectations in a recent large clinical trial (2).  
DV has a single stranded RNA genome of positive polarity, encoding for a polyprotein 
which is co- and post-translationally processed into three structural proteins (capsid, 
prM, and envelope) and seven nonstructural proteins (NS1-NS2A-NS2B-NS3-NS4A-
NS4B-NS5) (3). The virus enters mammalian cells via receptor-mediated endocytosis. 
In the endosomal compartment, the low pH induces a conformational change in the 
envelope (E) protein triggering membrane fusion and thus, nucleocapsid release into 
the cytoplasm (4, 5). Disassembly of the nucleocapsid occurs by a poorly understood 
mechanism leading to the release of viral RNA into the cytoplasm of infected cells. 
Upon synthesis of viral proteins, massive intracellular membrane remodeling events 
occur, which is a conserved feature among plus-strand RNA viruses (6, 7). These 
rearrangements include membrane invaginations into the ER, which are the assumed 
ͷ 
sites of flavivirus genome replication, and can be observed in both mammalian and 
arthropod cells (8, 9). Nucleocapsid formation is thought to occur in close proximity to 
replication sites (9). The envelope is acquired by budding through the ER membrane 
into which the envelope proteins E and prM have been inserted. Assembled virions, 
stored within ER stacks in highly ordered arrays, are released from the cell via the 
conventional secretory pathway, where cleavage of the prM protein by furin, a protease 
residing in the trans-Golgi network (TGN), occurs. This cleavage is required to render 
DV particles infectious.
The mature capsid protein (C) is a highly basic protein of 12 kDa that forms 
homodimers in solution (10, 11). The three-dimensional structure of DV C protein was 
solved by NMR (12), indicating that the monomer consists of four alpha helices (1 to 
4). The longest helix, 4, extends away from the core of the protein. It has a high 
density of basic amino acid residues on the solvent-accessible surface that were 
proposed to interact with the viral RNA. On the opposite side of the molecule, the 
surface, formed primarily by 22 and 11, is largely uncharged and proposed to 
interact with membranes (12). Although the C protein is the least conserved amongst 
flavivirus proteins, both its charge distribution and structural properties are well 
conserved. 
We have recently reported the identification of a small-molecule inhibitor, ST-148, 
inhibiting replication of all DV serotypes with high potency (13). Intraperitoneal and 
intravenous administrations of ST-148 in the AG129 mouse model revealed good 
bioavailability of the compound, which significantly reduced plasma viremia and viral 
load in spleen and liver of DV-infected mice. Selection of ST-148-resistant viruses led to 
͸ 
the identification of a single S34L amino acid change in C protein, which was shown to 
confer resistance to ST-148. Additionally, in vitro binding studies of ST-148 to purified C 
protein suggested that the compound bound equally well to wildtype and S34L-
containing C proteins. Although these studies identified C protein as the primary target 
of ST-148, its mode-of-action remained unknown. In the present study we addressed 
this aspect by using a combination of biochemical, virological and imaging-based 
methods. We obtained evidence that ST-148 enhanced C protein self-interaction, 
providing an explanation for the observed impairment of DV assembly/release as well 
as entry competence of virus particles.
Material and Methods 
Antibodies and Sera. Mouse monoclonal antibodies recognizing human GAPDH (sc-
47724/0411) and human Lamin A/C (Sc-7292/636) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Mouse monoclonal antibody against human ATP5B 
(3D5 #ab14730) was purchased from Abcam, mouse monoclonal antibody against 
human Vimentin (VI-10) was obtained from GeneTex Inc. (Irvine, CA). Mouse anti-
Envelope monoclonal antibody (3H5-1) was purchased from ATCC. Mouse anti-capsid 
monoclonal antibody derived from hybridoma cells (6F3.1) was a kind gift of Dr. John G. 
Aaskov (Queensland University of Technology, Australia), rabbit polyclonal serum anti-
capsid was a kind gift of Dr. Andrea Gamarnik (Fundación Instituto Leloir, Argentina). J2 
mouse monoclonal anti-dsRNA antibody was purchased from English and Scientific 
Consulting (Szirak, Hungary). The secondary anti-mouse and anti-rabbit horse-radish 
͹ 
peroxidase-conjugated antibodies were purchased from Sigma-Aldrich (Sigma-Aldrich, 
Saint Louis, MO). 
Bioluminescence resonance energy transfer (BRET). For Donor-Saturation-Assays, 
293T cells were transfected in 24-well plates with 20 ng/well of the DNA construct 
coding for the BRET donor (Rluc-capsid) and increasing amounts (20 to 1000 ng/well) 
of the DNA construct coding for the BRET acceptor (YFP-capsid). Total amount of 
transfected DNA was completed to 1020 ng with pcDNA 3.1(+) empty vector. Forty-
eight hours after transfection, cells were washed with PBS and harvested in 290 µl PBS. 
For each sample, three aliquots of 90 µl were distributed to wells of a 96-well microplate 
(black-plates, flat bottom; NalgeneNunc, New York, US). Total YFP expression was 
measured by using a Mithras LB940 Plate reader (Berthold Technologies, Bad Wildbad, 
Germany), with excitation and emission filters set at 485 and 535 nm, respectively. The 
luciferase substrate coelenterazine H (PJK, Kleinblittersdorf, Germany) was then added 
to a final concentration of 5 M and luminescence and fluorescence emissions were 
measured consecutively using a Mithras LB940 plate reader. For BRET measurements 
filters were set to 485 nm for luciferase emission and 535 nm for YFP emission. Donor 
saturation curves were obtained by plotting the BRET values on the y axis and the ratio 
between the fluorescence of the acceptor (netYFP=YFP-YFP0, where YFP0 is the 
fluorescence value in cells expressing the BRET donor alone) and the luminescence of 
the donor on the x axis. For ST-148 dose-response curves, a 1:50 ratio of donor - 
acceptor (in the BRETmax range) was used, and various concentrations of ST-148 (10, 
5, 2.5, 1.25, 0.625, 0.312, 0.156, 0.078, 0.039, 0.019, 0.0097, 0.0048 µM) or the highest 
ͺ 
equivalent amount of DMSO solute, were added to each well 30 minutes before 
transfection. BRET ratios were calculated as described by Angers et al. (14). 
Cell culture. Huh7, VeroE6, BHK-21 and HEK-293T cells were maintained in 
Dulbecco's modified Eagle medium (DMEM; Invitrogen, Karlsruhe, Germany) 
supplemented with 2 mM L-glutamine, nonessential amino acids, 100 U of penicillin/ml, 
100 g of streptomycin/ml, and 10% fetal calf serum. Cells were passaged in regular 
intervals by trypsinization and replating of appropriate dilutions. 
Immunoblot analysis. Samples were denatured in 2x protein sample buffer (200 mM 
Tris [pH 8.8], 5 mM EDTA, 0.1% Bromophenolblue, 10% sucrose, 3% SDS, 1mM DTT) 
and incubated for 5 min at 95°C. Proteins were separated by SDS-polyacrylamide gel 
electrophoresis (PAGE) and transferred onto polyvinylidene difluorid membranes by 
using a MINI-SDS-PAGE wet-blotting apparatus (Bio-Rad, Munich, Germany). 
Membranes were blocked with 5% non-fat dry milk in PBS/0.5% Tween-20 (PBST) and 
incubated with primary antibodies (capsid 1:50; GAPDH 1:1000; Lamin A/C 1:1000; 
Vimentin 1:1000; ATP5B 1:1000) by over-night incubation at 4°C. After 3 washes with 
PBST, membranes were incubated with secondary horse radish peroxidase-conjugated 
antibodies, developed with the Western Lightning Plus-ECL reagent (Perkin Elmer; 
Waltham, MA) and bands were imaged using an Intas ChemoCam Imager 3.2 (Intas, 
Göttingen). 
ͻ 
Immunofluorescence analysis. Huh7 cells were seeded onto glass coverslips in 24-
well plates at a density of 6×104 cells per well and infected on the next day with DV or 
DVS34L at a MOI of 1. 4h p.i. ST-148 was added at a final concentration of 10 µM. For 
quantification of lipid droplets (LDs) and co-staining of capsid with dsRNA, 48h after 
infection cells were fixed with 4% paraformaldehyde (PFA) (Applichem GmbH, 
Darmstadt, Germany), 4% sucrose and processed exactly as previously described by 
using a rabbit anti-capsid antibody (1:1000), a mouse anti-dsRNA (1:500) and Bodipy-
488 (1:500), which stains neutral lipids (15). Secondary staining was carried out using 
anti-mouse Alexa 546 and anti-rabbit Alexa-633-conjugated antibodies. All images were 
processed using the ImageJ software package (National Institutes of Health, Bethesda, 
MD). Background calculated from mock-infected cells was subtracted (-25 pixel) and the 
566 and 488 nm channels were smoothened with mean function set at 1.0. For 
visualization and quantification of nuclear and cytosolic capsid, cells were fixed with 4% 
PFA for 10 min at room temperature and permeabilized with 0.5% (vol/vol) Triton X-100 
in PBS. Primary staining was carried out by 45-min incubation with a mouse anti-capsid 
antibody, diluted in PBS containing 3% goat serum. After extensive washes with PBS, 
secondary staining was carried out by a 45-min incubation with an Alexa 568-
conjugated secondary antibody diluted 1:1,000 in PBS containing 3% goat serum. 
Nuclear DNA was stained with 4,6-diamidino-2-phenylindole (DAPI) (Molecular Probes, 
Karlsruhe, Germany). For staining of LDs, Bodipy-488 was added (1:500 dilution) to 
each coverslip for 10 min at room temperature. Samples were mounted on glass slides 
with Fluoromount G (Southern Biotechnology Associates, Birmingham, AL) and images 
were acquired using a Leica CTR MIC fluorescence microscope or a Nikon Eclipse Ti 
ͳͲ 
spinning-disc confocal laser microscope. Immunofluorescence signals were quantified 
using ImageJ, and images were assembled with the Adobe Photoshop software 
package. For quantification of LD size and number, cells were stained as described 
above, imaged using a 63x objective, and the size and number of Bodipy-488-stained 
LDs was calculated by using ImageJ. For each condition, at least 10,000 LDs in more 
than 500 cells and 8 - 10 view fields were examined. 
Infectivity assay. For determination of virus titers, Huh7 target cells were seeded into 
96-well plates (104 cells/well) the day before infection. Cells were inoculated with serial
dilutions of virus-containing supernatants that had been filtered through a 0.45-m-pore-
size filter. Infected cells were detected by immune staining of the E protein using the 
mouse anti-E antibody (3H5-1; diluted 1:500) and secondary horseradish peroxidase-
conjugated antibody (1:200). Virus titers (the 50% tissue culture infective dose 
[TCID50]/ml) were calculated as previously reported (16). 
Determination of antiviral activity of ST-148. Huh7 cells were seeded into 12-well 
plates at a density of 1x105 cells per well and incubated overnight. Cells were then 
infected with DV, DVS34L, DVR2A or DVR2AS34L at a MOI of 0.1 in the presence of a 
range of compound concentrations. Seven compound concentrations (25, 8, 2.5, 0.8, 
0.25, 0.025, 0.008 µM) were used to determine the 50% effective concentration (EC50). 
After 1h, inoculi were removed and fresh medium containing various concentrations of 
ST-148 were added to each well. After a 48h incubation period, supernatants were 
harvested, filtered through a 0.45-m-pore-size filter and 10-fold dilutions were used to 
ͳͳ 
determine virus titer by plaque assay as described previously (13). EC50 values were 
calculated by fitting the data to a four-parameter logistic model (variable slope, 
nonlinear regression model) to generate a dose-response curve by using the GraphPad 
Prism 5.0 software package (GraphPad Software, San Diego, CA). From this curve, the 
concentration of compound that reduced virus-induced cytopathic effect (CPE) by 50% 
was calculated. 
In vitro transcription and RNA transfection. In vitro transcripts were generated as 
previously described (17). For RNA transfection, Huh7 or 293T single-cell suspensions 
were prepared by trypsinization, washed with PBS, and resuspended at a concentration 
of 1x107 cells (Huh7) or 1.5x107 cells (293T) per ml in Cytomix, supplemented with 2 
mM ATP and 5 mM glutathione. Next, 10 g of subgenomic or genomic in vitro
transcript, was mixed with 400 l of the cell suspension and transfected by 
electroporation using a Gene Pulser system (Bio-Rad) and a cuvette with a gap width of 
0.4 cm (Bio-Rad) at 975 F and 270 V. Cells were immediately diluted into 20 ml of 
DMEM cplt and seeded in the appropriate format (1ml/well in 24-well plates; 2 ml/well in 
12-well plates; 15 ml/dish in 15 cm-diameter dishes).
Lentivirus production. The pWPI-BLR-capsid constructs encoding for either the 
capsid wildtype or containing the S34L mutation, and the pWPI-Puro-prM-E constructs 
were co-transfected into 293T cells with plasmids encoding Gag-Pol of HIV and the G-
protein of vesicular stomatitis virus (ratio 3:3:1) as previously reported (16). After 48 and 
ͳʹ 
72h, supernatants were harvested, clarified through 0.45 µm pore size filters, pooled 
and stored in aliquots at -20°C until use. 
Molecular modeling. For protein-protein docking, the NMR structures of DV capsid 
dimers (PDB entry: 1R6R) (12) were used. The 20 dimer models were compared using 
the MOE Protein Consensus tool (version 2010.10, Chemical Computing Group Inc., 
Montreal, QC, Canada) and the 5 most different structures were selected for rigid 
protein-protein docking. Each dimer model was used both with the wildtype sequence 
and with the S34L mutation, inserted with the MOE Mutate tool. All structures were 
prepared using the Schrödinger Maestro Protein Preparation Wizard (version 9.5, 
Schrödinger, LLC, New York, NY, 2013). For each model, protein-protein docking was 
performed with Schrödinger BioLuminate (version 1.2, Schrödinger, LLC, New York, 
NY, 2013) Piper using the same dimer structure for both receptor and ligand entries. 
Standard mode was applied, probing 70,000 ligand rotations and giving a 0.21 bonus to 
the complexes that involved Ser34 in the interactions. The best tetramer model was 
selected by visual inspection. 
All of the molecular dynamics (MD) simulations were computed with GROMACS 
(version 4.5.3) (18) and AMBER99 force field. All simulations were performed on both 
wildtype and S34L mutant structures and in the latter case, the mutation was inserted 
starting from the wildtype structure. PBC conditions were applied, using a cubic box with 
0.9nm minimum distance between the molecular system and the box. Explicit water 
molecules described with the TIP3P model were added and systems were neutralized 
with the addition of 72 Cl- ions. Missing ST-2148 topology parameters were computed 
ͳ͵ 
with Antechamber that is part of the Amber software package (version AMBER12, 
University of California, San Francisco). Atom partial charges were obtained with the 
AM1-BCC charge method, while atom types and force field missing parameters were 
assigned with the GAFF force field. The coordinate and topology files were then 
converted into GROMACS-compatible format with the acpype converter (Department of 
Biochemistry, University of Cambridge, UK). 
Prior to the production simulation, two energy minimizations were performed: first with 
steepest descendent and second, with conjugate gradient methods. Both energy 
minimizations were implemented for 3,000 steps (with a step size of 1 fs) with force 
tolerance of 100 kJ mol-1 nm-1 for steepest descent, and of 10 kJ mol-1 nm-1 for 
conjugated gradient. Successively, the protein atoms were constrained with a position 
restrain of 1,000 kJ mol-1 nm-2 and water molecules were relaxed with two 50 ps (50,000 
steps, step size of 1 fs) position restraint MDs. Coordinates, velocities and energy 
values were saved every 500 steps in both stages. The first position restraint MD was 
conducted in NVT conditions (constant number of atoms N, volume V and temperature 
T), allowing the system to be heated to 300 K with a v-rescale temperature coupling and 
0.1 ps time constant. Then, the second stage was performed in NPT conditions (with 
constant number of atoms N, pressure P and temperature T). Both temperature (with v-
rescale, temperature 300 K and time constant of 0.1 ps) and pressure coupling (with 
Berendsen algorithm, 1 bar pressure and time constant of 0.5 ps) were applied in this 
case. A 30 ns (15,000,000 steps with 2 fs step size) production simulation was run for 
each molecular system in the NPT conditions described above. Coordinates, velocities 
and energy values were saved every 1,000 steps. In all procedures, a 0.9 nm short 
ͳͶ 
range cut-off was applied for long-range electrostatic interactions that were calculated 
with the PME method, while short range non-bonded interactions were calculated within 
a cut-off of 1.4 nm. 
For ST-148 docking, each small molecule docking simulation was performed using 
Schrödinger Maestro (version 9.5, Schrödinger, LLC, New York, NY, 2013). Prior to 
docking, the protein and ST-148 were prepared with the Protein Preparation Wizard tool 
and the LigPrep, respectively, generating all possible tautomers and ionisation states at 
pH 7.0 ± 2.0. For each docking, the grid was generated with Glide defining appropriate 
centre and box sizes. Docking was performed with Glide standard precision (SP) mode, 
sampling nitrogen inversions and ring conformations and penalizing non-planar 
conformations for amides. The 25 poses generated were then refined with the SP 
mode. 
Plasmid constructs. Plasmids encoding for the subgenomic replicon (pFK-sgDVsR2A) 
and the full-length genomes pFK-DVs and pFK-DVs.R2A (carrying a Renilla luciferase 
reporter gene) are based on the DV-2 16681 strain, and have been described recently 
(17) (Fig. 1A). The S34L amino acid substitution conferring resistance to ST-148 was
introduced into the capsid coding region by site-directed mutagenesis using PCR with 
the external primers capsid_AgeI_frw (5-AACAAACCGGTAGAGCCGAGGGCAG-3) 
and capsid_NaeI_rev (5-TAATGATCATGCCGGCAGATCTGCG-3), and the internal 
primers capsid_S34L_frw (5-CAAAGAGATTCCTACTTGGAATGCT-3) and 
capsid_S34L_rev (5-AGCATTCCAAGTAGGAATCTCTTTG-3; mutated codon 
underlined) and inserted into pFK_DVs and pFK_DVsR2A via AgeI/NaeI restriction 
ͳͷ 
sites. Given numbers refer to amino acid positions in the capsid open reading frame. 
For BRET experiments, the Gateway® technology was employed. The wildtype or S34L 
capsid coding regions as well as the DV NS4A coding region (which served as negative 
control) were amplified by PCR using full-length genomes as templates and the external 
primers s_mC_LM_N (5-TAGGTACCGGATGAATAACCAACGGAAAAAGG-3) and 
as_mC_LM_N (5-TAGATATCCTATCTGCGTCTCCTATTCAAGATG-3) and 
s_NS4A_LM_N (5-TAGGTACCGGTCTCTGACCCTGAACCTAATCACAG-3) and 
as_NS4A_LM_N (5-TAGATATCCTATCTCTGTTTTTCAGGTTCTGG-3), respectively, 
to generate intermediate entry clones. Amplicons were inserted into the entry vector 
backbone (pENTR4 vector, Invitrogen, Karlsruhe) via KpnI/EcoRV restriction sites. 
Gateway® destination clones encoding for humanized luciferase renilla and YFP were 
generated using standard cloning PCR-based procedures, thereby creating pT-Rex-
DEST30-nt-RL and pT-RexTM-DEST30-nt-YFP plasmids. Finally, expression clones 
were generated by LR-reaction according to the manufacturers instructions with slight 
modifications. Briefly, 150 ng entry clone, 150 ng destination vector, 1 µl LR Clonase 
enzyme mix, adjusted to a total volume of 10 µl with 10 mM Tris-HCl [pH 8.0], were 
incubated at 25°C for 2 h or overnight. The reaction was stopped by the addition of 1 µl 
Proteinase K (2 µg/µl) and incubation at 37°C for 10 min. Finally, the complete reaction 
mixture was transformed into competent E. coli DH5 cells. Isolated plasmids were 
sequence-verified and expression confirmed by Western blot analyses of transfected 
cells and by fluorescence microscopy (data not shown). For production of lentiviruses 
expressing the structural proteins, the capsid and prM-Envelope coding sequences 
were amplified by PCR using full-length genomes as template and the following primers 
ͳ͸ 
containing given unique restriction sites, an AUG initiation codon and a stop codon at 
the 3 end: capsid_SbfI_frw (5-
ATGTATGTCCTGCAGGGCCACCATGAATAACCAACGGAAAAAGGCGAAAAAC-3), 
capsid_MluI_rev (5-
CTAACATTTACGCGTCTATCTGCGTCTCCTATTCAAGATGTTCA-3), prM-E_SbfI_frw 
(5-TATGTCCTGCAGGGCCACCATGAGAGCCGAGGGCA-
GGGGAAGTCTTCTAACATGCGGGGACGTGGAGGAAAATCCCGGGCCCTCTGCCG
GCATGATCATT-3) and Env_MluI_rev (5-CTAACATTTACGCGTCTAGGCCTGCA-
CCATGACTCCCAAATACAGTGT-3). A Thosea asigna virus (TaV) 2A coding 
sequence mediating self-cleavage was inserted upstream of the capsid anchor 
sequence to ensure cleavage at the capsid-anchor junction. The capsid coding region 
was inserted into a pWPI-BLR vector carrying the Blasticidin resistance gene, the prM-E 
cassette was inserted into a pWPI-Puro vector encoding a puromycin resistance gene 
as previously described (16). All constructs were verified by nucleotide sequence 
analysis. 
qRT-PCR analysis. Total cellular RNA from ~5 × 105 virus-infected cells and 1/10 of 
corresponding supernatants was isolated by using the NucleoSpin RNA II kit 
(Macherey-Nagel, Düren, Germany) as recommended by the manufacturer. The cDNA 
was prepared using a High Capacity cDNA reverse transcription kit (Applied 
Biosystems, Life Technologies). Quantitative real-time PCR (qRT-PCR) was carried out 
using an ABI Prism 7000 sequence detector system (Applied Biosystems, Foster City, 
CA). For each primer set, reactions were conducted in triplicate by using the Green Dye 
ͳ͹ 
RT-PCR master mix (PJK GmbH, Hilden, Germany) according to the manufacturer's 
instructions with the following primers binding to a region within the DV NS5 coding 
sequence (primer polarities are indicated): sDV2-9687 (5-
GCCCTTCTGTTCACACCATT-3; forward); asDV2-9855 (5-
CCACATTTGGGCGTAAGACT-3; reverse). Total volume of the reaction mixture was 
15 l and reactions were performed in two stages: stage 1, 15 min at 95°C; stage 2, 40 
cycles of 15 s at 95°C and 60 s at 60°C. Quantities of DV RNA were calculated by using 
serial dilutions of known amounts of DV in vitro transcripts that were processed in 
parallel as previously described (19). 
Sequence alignments. Sequence alignments were performed with the following 
flaviviruses (UniprotKB/Swiss-Prot accession numbers are given in italics): DV-1 
(Brazil/97-11/1997)/P27909; DV-2 (Thailand/16681-PDK53)/P29991; DV-3
(Martinique/1243/1999)/Q6YMS3; DV-4 (Thailand/0348/1991)/Q2YHF0; WNV/P06935; 
Yellow Fever (Ivory Coast/1999)/Q6J3P1; Japanese Encephalitis Virus (SA-
14)/P27395; Kunjin virus (MRM61C)/P14335; St.Louis Encephalitis virus (MS1-
7)/P09732. 
Statistical analyses. Statistical analyses were performed by applying the two-tailed, 
unpaired Students t-test. In some cases, indicated in the results section, data were 
analyzed with one-way analysis of variance (ANOVA) and Dunnett's post-hoc test for 
multiple comparisons to non-treated controls or ANOVA and Tukeys post-hoc test to 
compare every group to each other, as indicated in related figure legends. Microsoft 
ͳͺ 
Excel software package and GraphPad Prism (ver. 5.0) were used for statistical 
analyses.  
Subcellular fractionation. For subcellular fractionation of cytosolic, membrane, nuclear 
and post-nuclear fractions, the Qproteome Cell Compartment Kit, purchased from
Qiagen (Hilden, Germany), was used as recommended by the manufacturer. In brief, 
106 Huh7 cells were seeded into 10 cm-diameter dishes the day before infection. Cells 
were infected with either DV wildtype or DVS34L with an MOI of 1 for 4h at 37°C, washed 
three times with PBS and complete medium containing 10 µM of ST-148 or DMSO was 
added to the cells. After 48h cells were washed 3 times with ice-cold PBS, trypsinized 
and collected by 5 min low speed centrifugation (700xg). Collected fractions were 
acetone-precipitated overnight at -20°C and resuspended in equal volumes of 2xSDS 
loading buffer. 1/10 of total cell suspension was saved as input and equal amounts of 
each fraction were subjected to SDS 12% PAGE as described above. Fraction purity 
was evaluated by determining amounts of cytosolic (GAPDH), membrane (ATP5B), 
nuclear (Lamin A/C) and post-nuclear/cytoskeletal (Vimentin) markers. 
Production of trans-complemented DV particles. To produce trans-complemented 
DV particle (DVTCP) stocks, 293T cells were electroporated with 10 µg of subgenomic 
sgDVR2A replicon RNA, seeded into 15cm-diameter dishes and incubated at 37°C. On 
the next day, cells were inoculated with lentiviral particles encoding for capsid and prM-
E for 8h. Cells were carefully washed 3 times with PBS, fresh medium was added and 
cells were cultured at 33°C for 4 - 6 days. Supernatants were pooled, filtered through a 
ͳͻ 
0.45 m-pore-size filter and 15 mM Hepes [pH 7.2-7.5] was added to the medium. 
DVTCP stocks were stored in aliquots at -80°C until use. 
Transient replication assay and DVTCP-based virus entry assay. Huh7 cells 
transfected with full-length DVR2A RNA were seeded into 12-well plates. Replication 
was determined by measuring luciferase activity in cell lysates 4, 24, 48, 72 h after 
transfection. For harvest, cells were washed once with PBS and lysed by adding 200 l 
lysis buffer as previously described (19). Cells were frozen immediately at 70°C and 
after thawing, lysates were resuspended by gentle pipetting. For each well, 20 l lysate, 
mixed with 400 l assay buffer (25 mM glycylglycine, 15 mM MgSO4, 4 mM EGTA, 1 
mM DTT, 2 mM ATP, 15 mM K2PO4 [pH 7.8], 1.42 M coelenterazine H), were 
measured for 10 sec in a luminometer (Lumat LB9507, Berthold, Freiburg, Germany). 
Each well was measured in duplicate. To determine the amount of infectious virus 
particles released into culture supernatants 72h after electroporation, naïve Huh7 cells 
were inoculated with these supernatants and 48h later luciferase activity was 
determined. Kinetics of virus replication were calculated by normalizing the relative light 
units measured at a given time point to the respective 4h value. Four hours-values, 
reflecting transfection efficiency, were comparable among samples and biological 
replicates, and no statistically significant differences were observed. For DVTCP
experiments, Huh7 cells were inoculated with particles composed of wildtype capsid 
protein or containing the S34L resistance mutation for 90 min at 37°C. At different times 
before, during or after inoculation, 10 µM of ST-148 or 0.1% DMSO were added to the 
medium. Replication was measured 48h after inoculation. 
ʹͲ 
Virucidal assay. Preparations of DV and DVS34L particles (corresponding to 3.8x106
TCID50/ml) were incubated for 1h at 37°C in DMEM containing 10 µM ST-148 or 0.1 % 
DMSO. Viruses were serially diluted and the remaining infectivity was measured by 
TCID50 assay. 
Analysis of infected cells by transmission electron microscopy. Huh7 cells (6x104) 
were seeded onto glass coverslips and around 16h later, cells were infected with 3 MOI 
of either DV or DVS34L. After 4h cells were washed three times with pre-warmed PBS 
and DMEM containing 10 µM of ST-148 or 0.05% DMSO was added. After a 48h 
incubation period cells were fixed and prepared for transmission electron microscopy as 
described previously (20). 
Results 
ST-148 is a potent inhibitor of DV. ST-148 (Fig. 1B) was identified by a high-
throughput screen as a potent inhibitor of DV, exhibiting anti-viral activity against all four 
serotypes and reducing viremia in vivo (13). In the first set of experiments we confirmed 
the anti-viral potency of ST-148 by using synthetic DV-2 based clones derived from the 
isolate 16681 (Fig. 1A) (17), which was used throughout the study. To determine the 
inhibitory potency of the compound, Huh7 cells were infected with DV or the DVR2A 
luciferase reporter virus, encoding either the wildtype (wt) or the previously identified 
ST-148 resistance mutation in capsid protein (S34L). Released infectivity was assessed 
by PFU titration assay using culture supernatants harvested 48h after infection. As 
ʹͳ 
previously observed for the DV-2 NGC strain (13), ST-148 also inhibited 16681-derived 
DV with EC50s in the low nanomolar range (52 and 37 nM, respectively; Fig. 1C and 
Table 1). These values were around 220 - 300-fold higher in the case of the DVS34L and 
DVR2AS34L resistant mutants, respectively, thus corroborating our previous findings and 
validating the anti-viral potency of ST-148, independent from the used DV strain. 
ST-148 does not affect viral RNA replication but inhibits DV spread. Previous time-
of-addition studies have shown that ST-148 is effective when added up to 12h post 
infection, suggesting a post-entry mechanism of action (13). However, the virus yield 
inhibition assays used allowed several cycles of viral replication and therefore, possible 
effects on DV entry, viral RNA replication and assembly or release of virus particles 
could not be distinguished. In order to dissect the possible impact of ST-148 on different 
steps of the viral replication cycle, we first assessed viral RNA replication and virus 
spread by using a DVR2A luciferase reporter virus and addition of ST-148 4h post 
infection, i.e. after virus entry had taken place. Virus replication in infected cells was 
determined 24, 48 and 72 h after infection by luciferase assay (Fig. 2A). Effects on virus 
production were quantified by using culture supernatants of infected and drug-treated 
cells harvested 72h after inoculation, infection of naïve Huh7 cells and measuring 
luciferase activity 48h later (Fig. 2B). While viral RNA replication was not affected by 
ST-148, luciferase counts detectable in the reinfection assay were decreased 60 to 
80%, arguing that the compound reduced virus production (Fig. 2A and B, respectively). 
To corroborate that the antiviral effect of ST-148 observed was due to virus production 
and independent from virus entry under these conditions and to investigate the 
ʹʹ 
phenotype of the ST-148-resistant mutant, we next determined the replication 
competence of either virus in Huh7 cells that had been transfected with the 
corresponding DV genomes, thus deliberately bypassing the entry step. Under these 
conditions, both viruses replicated comparably regardless of ST-148 treatment (Fig. 
2C). However, a significant ~80% reduction of amounts of infectious virus was observed 
exclusively for the wildtype virus (Fig. 2D), thus confirming a selective inhibition of the 
late steps of the DV replication cycle by ST-148. 
ST-148 inhibits the production of infectious DV particles. In order to determine 
whether the reduction of virus production resulted from an impairment in virus particle 
release or a reduction of their specific infectivity, we next performed infectivity and viral 
RNA titration experiments. Huh7 cells were infected with 1 MOI of DV and various 
concentrations of ST-148 were added 4h after infection. Amounts of released viral RNA 
and infectious DV particles in the supernatant were determined 48h later by qRT-PCR 
and TCID50 assay, respectively (Fig. 3A, B). These experiments revealed a dose-
dependent reduction of virus titers as deduced from the up to 10-fold lower amounts of 
infectivity and viral RNA observed at highest inhibitor concentration. 
Next we investigated whether the observed reduction of virus titer resulted from an 
impairment of virus spread or from a direct block in virus particle production by using a 
single-cycle infection experiment. Huh7 cells were infected with 1 MOI of DV or DVS34L
and incubated for 48h to allow for nearly complete infection of the cell monolayer (Fig. 
3C). Released viruses were then removed by extensive washing and medium 
containing DMSO, ST-148 or Brefeldin A that served as positive control, was added to 
ʹ͵ 
the cells. Cells were incubated for just 12h, which is the estimated length of a single 
complete DV replication cycle ((21) and B. Schmid, unpublished observations). 
Therefore, re-infecting or super-infecting virus produced within this time period would 
not significantly contribute to extracellular virus titer. Viral RNA contained within infected 
cells or released into the culture supernatant was quantified by RT-qPCR. In addition, 
infectivity titers were determined by limiting dilution assay. Under these conditions, a 
highly significant reduction of ~90% of infectivity amount was observed for the drug-
treated wildtype virus, while the S34L mutant was unaffected by ST-148 treatment (Fig. 
3D). Concomitantly, ST-148 profoundly reduced secretion of viral RNA by ~70% in case 
of DV wildtype, while no statistically significant reduction could be observed for the 
DVS34L-resistant variant (Fig. 3E). As expected, in both cases BFA treatment drastically 
reduced titers of both viral RNA and infectivity (Fig. 3D and E; black columns), 
consistent with an earlier report (22). In conclusion, these results suggest that ST-148 
reduces DV particle production. The concomitant reduction of extracellular infectivity 
and viral RNA amounts implies that ST-148 has no significant effect on specific 
infectivity of DV particles. 
ST-148 additionally inhibits DV entry. Since viral RNA replication in the presence of 
ST-148 was unaltered and the observed inhibitory effect of the drug on 
assembly/release of DV particles was rather modest, as compared to the high inhibitory 
potency observed by virus yield inhibition assay, we hypothesized that ST-148 might 
have an additional effect on virus entry. To verify this hypothesis, we developed a trans-
complementation system, which allows production of infectious virus-like particles 
ʹͶ 
containing a subgenomic replicon and unable to spread in cell culture (23, 24, 25, 26, 
27). These particles that we call DV trans-complemented particles (DVTCP) in analogy to 
our earlier report on HCVTCP (16), were obtained by transfecting subgenomic replicons 
into helper cells that provide the structural proteins in trans (Fig. 4A). Since packaged 
subgenomic replicon RNAs lack the region encoding for the structural proteins, DVTCPs 
only support a single round of infection. Moreover, DVTCPs encode the Renilla luciferase 
reporter gene and therefore, single-round infection can be measured as a function of 
luciferase activity. 
Taking advantage of luciferase encoding DVTCPs composed of wildtype or S34L 
capsids, we performed time-of-addition studies by treating cells before, during or at 
different times after infection with ST-148 and measured luciferase activity 48h later. As 
shown in Fig. 4B, maximal antiviral activity was achieved when cells were treated prior 
to or during infection, reducing viral replication up to 70% (p<0.001). Significant antiviral 
effect was still obtained up to 120 min post-infection (i.e. 30 min after removal of virus 
inoculum) whereas treatment at later time points had no effect (Fig. 4B). 
To exclude a general non-specific virucidal effect of ST-148 on DV particles, we 
incubated high titer virus stocks of DV or DVS34L with 10 µM of ST-148 for 1h at 37°C 
and determined infectivity titer after extensive dilution by TCID50 assay (Fig. 4C). Under 
these conditions no significant reduction of viral infectivity could be observed. Taken 
together, these data suggested that ST-148 specifically blocks DV entry, which is not 
due to a virucidal effect. 
ʹͷ 
ST-148 does not affect co-localization of capsid with lipid droplets and dsRNA but 
increases clustering of virus particles in the ER. In DV-infected cells C protein 
resides both in the cytoplasm and nucleus (28, 29, 30). Cytosolic capsid protein was 
shown to localize around LDs (15) and in close association with vesicle packets, which 
are sites of RNA replication (30, 31, 32), while nuclear capsid protein accumulates in 
nucleoli and was reported to interact with nuclear proteins (33, 34, 35). In order to 
investigate whether ST-148 would affect the recruitment of capsid to LDs and its co-
localization with dsRNA, we performed co-localization studies using DV-infected cells 
treated with ST-148. Treatment was started 4h post infection until cells were fixed by 
using paraformaldeyde and low concentration of TritonX-100 as reported earlier (15). As 
shown in Fig. 5A, we could not observe a difference between inhibitor- and DMSO-
treated cells and co-localization of capsid around LDs or with dsRNA appeared 
unaltered. To rule out possible effects of ST-148 on LD morphology or abundance, we 
quantified their average size and number per cell (Fig. 5B, C). While LD size was 
comparable between DMSO and ST-148-treated cells, the overall amount of LDs per 
cell appeared slightly reduced upon drug treatment, but this difference was not 
statistically significant. In agreement with previous reports (15), we could observe an 
increase in the overall amount of LDs/cell in DV infected cells (Fig. 5C). These results 
indicate that ST-148 does not alter recruitment of capsid around LDs or its co-
localization with dsRNA. 
With the aim to gain insights into the possible mode-of-action of ST-148, we next 
investigated the effect of the compound on the ultrastructural morphology of DV-infected 
cells treated with ST-148 by using transmission electron microscopy (Fig. 5D). Both DV- 
ʹ͸ 
and DVS34L-infected cells contained the characteristic membrane invaginations, which 
have been proposed to represent viral replication factories (vRFs) (9), and virions 
forming regular arrays within the ER. Treatment of DV-infected cells with ST-148 did not 
affect the morphology of vRFs, consistent with a lack of inhibition of viral RNA 
replication, whereas the overall amount of virions was drastically reduced. Interestingly, 
in case of the wildtype virus, the fewer virions that could be found intracellularly in ST-
148 treated cells appeared to form larger arrays as compared to control cells (Fig. 5E). 
This phenotype was specific and not found with ST-148 treated cells that had been 
infected with the DVS34L resistant mutant (Fig. 5E). 
ST-148 alters intracellular distribution of capsid protein. Several lines of evidence 
point towards a functional role for flavivirus capsid within the nucleus of infected cells. 
For instance, West-Nile virus capsid protein has been proposed to dynamically shuttle 
between the cytoplasm and the nucleus and the temporal regulation of this process was 
suggested to prevent pre-mature encapsidation of viral RNA at early stages of infection 
(33, 36). For Japanese encephalitis virus, it was shown that disrupting nuclear 
localization affected virus replication and pathogenesis in mice (37). In case of DV, 
several studies reported the presence of C protein in the nucleoli of infected cells (28, 
33, 34, 38). Moreover, DV C protein has been shown to interact with a number of 
nuclear proteins, including hnRNP-K and histones (39, 40, 41); however, the relevance 
of nuclear localization of DV C protein with respect to viral replication is unclear (28). In 
the light of these reports, we investigated the influence of ST-148 on nuclear 
accumulation of C protein by using an immunofluorescence protocol that includes 
ʹ͹ 
permeabilization of the nucleus. Consistent with earlier reports (15), under these 
conditions we detected capsid both in the cytosol and within the nucleoli of infected cells 
(Fig. 6A, B). In case of DV wildtype-infected cells, ST-148 treatment increased capsid 
accumulation within the nucleoli as compared to DMSO-treated control cells. In 
contrast, although the S34L-containing capsid protein exhibited enhanced nuclear 
localization, this subcellular distribution was not affected by ST-148-treatment. 
To further investigate the intracellular distribution of C protein upon ST-148 treatment, 
we generated subcellular fractions of DV- or DVS34L-infected cells by using a method 
that allows separation of cytosolic, membrane, nuclear and insoluble post-nuclear 
proteins (Fig.6C). This approach revealed that ST-148 treatment reduced abundance of 
cytosolic wildtype C protein, concomitant with an increase of this protein in the post-
nuclear, insoluble fraction (Fig. 6C). In contrast, subcellular distribution of the S34L 
capsid protein was not affected by treatment of infected cells with the compound (Fig. 
6C). In conclusion, these results show that ST-148 reduces abundance of cytosolic 
capsid concomitant with an accumulation of the protein in nuclear, detergent-resistant 
aggregates, which might contribute to the observed reduction of virus particle 
production. 
ST-148 increases capsid self-interaction. DV capsid forms dimers (10) and 
eventually also oligomers during nucleocapsid assembly. It is plausible to assume that 
stability of capsid oligomers might be important for assembly of infectious virus particles 
and for uncoating during virus entry. Since ST-148 appeared to affect both the efficiency 
of virus production and entry properties of DV particles, we assumed that this 
ʹͺ 
compound might affect capsid self-interaction. To address this assumption, we used a 
bioluminescence resonance energy-transfer (BRET) based assay, which allows 
investigating the protein of interest within its physiologically relevant subcellular 
compartment in live cells (42). BRET is detected when energy emitted by the Renilla 
luciferase (Rluc) of a donor fusion protein is transferred to an acceptor YFP-fusion 
partner following catalytic degradation of the cell-permeable Rluc substrate 
coelenterazine H (Fig. 7A) (14). In the first set of experiments, we performed donor-
saturation-assays (DSA) by using capsid proteins fused N-terminally either with YFP or 
Rluc (Fig.1A). As shown in Fig. 7A, a nonlinear increase in BRET intensity and a rapid 
saturation of the BRET signal was detected when a fixed amount of the Rluc-capsid 
construct was co-expressed with increasing quantities of the YFP-capsid construct. This 
pattern clearly indicated specific capsid self-interaction. In contrast, increasing 
concentrations of a YFP-NS4A construct (used as negative control) co-expressed with 
the Rluc-capsid construct resulted only in a weak and linear increase of BRET, which is 
a characteristic pattern for non-interacting proteins (43, 44). 
Besides providing information on the specificity of a given interaction determined by 
BRET, additional parameters, such as BRETmax, i.e. the BRET signal at which the 
saturation curve reaches a plateau, and BRET50, i.e. the concentration of acceptor 
giving 50% of BRETmax, can be extrapolated from DSA experiments. While BRETmax is a 
function of the distance and orientation between the donor and acceptor within their 
oligomeric complex, BRET50 reflects the relative affinity between the fusion proteins. As 
deduced from the BRET50 values, the S34L mutation did not alter capsid self-interaction 
and no significant difference between the oligomerization profiles of wildtype and S34L 
ʹͻ 
capsid proteins could be observed (BRET50 of wildtype = 4.99±1.071; BRET50 of the 
S34L mutant = 4.01±0.67) (Fig. 7A). 
Next, we evaluated the effect of increasing concentrations of ST-148 on wildtype and 
S34L capsid self-interaction under conditions of BRETmax, i.e. ~50-fold excess of YFP-
capsid plasmid relative to the Rluc-capsid plasmid (Fig. 7B). Under these conditions, we 
observed a dose-dependent increase of the BRET ratio, first detectable at 156 nM of 
ST-148 and reaching a plateau at 1.25 µM. This increase in BRET signal was only 
found with the wildtype capsid protein, whereas the oligomerization status of the S34L 
capsid appeared unaffected for all tested concentrations, thus demonstrating specificity 
of the ST-148-mediated enhancement of capsid self-interaction. These results support 
the notion that ST-148 directly affects capsid protein. The correlation between antiviral 
efficacy and enhancement of capsid self-interaction argues that increased capsid 
oligomerization might be responsible for the antiviral activity of ST-148. 
In silico modeling corroborates ST-148-mediated stabilization of inter-dimer 
capsid interactions. To further understand the mode of action of ST-148 at the 
molecular level, we performed molecular modeling studies of wildtype and S34L capsid 
protein by using protein-protein docking, molecular dynamics (MD) simulations and 
small molecule docking. These studies were based on the NMR structures reported by 
Ma et al. (PDB accession no 1R6R) (12). Since capsid protein was reported to form 
stable dimers in solution (10, 12), they were considered as fundamental units and 
therefore formation of tetramers was simulated. Since we observed nuclear 
accumulation of capsid in the presence of ST-148, only tetramers that did not involve 
͵Ͳ 
nuclear localization sequences (NLS) (28) at the interaction surfaces were considered, 
assuming that otherwise these NLS were hidden. Likewise, complexes that did not 
involve LD-binding domains (12, 45, 46) were preferred, because no effect on capsid-
LD colocalization by ST-148 was detected. Priority was given to complexes in which the 
protein-protein interaction surface involved Ser34 as this amino acid residue was 
altered in case of the ST-148 resistant DV mutant (Fig.8A). Symmetry of the tetramer 
was not considered as an important element as cryo-EM data revealed that DV 
nucleocapsid is disordered (47, 48, 49). 
Two 30 ns molecular dynamics (MD) simulations were performed on the best tetramer 
complex: one on the wildtype and one on the same structure containing the S34L 
mutation. In accordance with the BRET data, the two structures behaved similarly, 
indicating no differences between the wildtype and the mutant proteins in the absence 
of the inhibitor. In both cases the tetramer quaternary structure changed during the first 
2 ns (supplemental material, Video S1 and S2, respectively) and was stable for the rest 
of the simulation, suggesting that the system reaches equilibrium. 
By using the energy-minimized tetramer structures of both the wildtype and S34L 
capsid, we next docked ST-148 using a 30 Å grid centered on the two Ser34 (or Leu34 
in case of the mutant) residues at the dimer-dimer interface, and examined the obtained 
ST-148 pose for wildtype and the S34L mutant over a 30 ns MD simulation.
Comparable to the MD simulations in absence of ligands, a similar change in the 
quaternary structures of both wildtype and S34L capsid could be observed during the 
first 2 ns (Video S3 and S4 in supplemental material), and then the system reached 
equilibrium. Fig. 8B shows the final MD result structures obtained for the wildtype 
͵ͳ 
protein in absence (left panel) or in presence of ST-148 (right panel). In case of the 
wildtype capsid, ST-148 bound the complex in a cleft between the 1 helix of one dimer 
and 1 and 3 helices of the other dimer and remained stable at this site for the last 10 
ns of the simulation (Video S5 in supplemental material). Noteworthy, ST-148 induced a 
shift of the 3 and 2 helices (Fig. 8C, dashed arrows), creating the ligand cleft and 
stabilizing further compound binding. Conversely, in case of the S34L mutant protein, 
the compound did not bind a cleft at the dimer-dimer interface, but explored more than 
one site in a solvent-exposed area of one dimer (Video S6 in supplemental material). 
To confirm this difference in ligand binding between the two structures, we used the 
stable wildtype tetramer-ligand complex corresponding to the equilibrium state and 
docked ST-148 into the pocket identified during the MD, by using a 20 Å grid (Fig. 8D). 
This docking confirmed that ST-148 is able to bind the tetramer at the dimer-dimer 
interface and the same compound conformation obtained from the MD was reproduced. 
In case of the wildtype structure, the binding site is formed primarily by residues Val26, 
Leu29, Arg41 and Arg68 of one dimer and Ser34 of the other dimer. As shown in Fig. 
8D, the phenyl moiety of ST-148 binds Phe33 with a - stacking interaction, while the 
thieno[2,3-b]pyridine portion of ST-148 is tethered between Ser34 and Arg68, where the 
positive charge interacts with the electron-dense aromatic system. Furthermore, as ST-
148 is highly lipophilic, its binding is enhanced by the high number of hydrophobic 
residues forming the pocket. As the compound is in close contact with Ser34, a leucine 
residue at this site creates a steric clash between the protein and the ligand (Fig. 8E), 
confirming that the S34L resistance mutation does not allow ST-148 to bind to the 
tetramer in the same way, consistent with the MD simulations. In summary, these 
͵ʹ 
results support the notion that ST-148 stabilizes capsid oligomerization and reveal a 
plausible model for compound binding to the capsid protein as well as binding inhibition 
by a distinct resistance mutation.
Discussion 
Capsid proteins of enveloped viruses have emerged as promising targets for the design 
of antiviral agents. In fact, the processes regulating both viral genome encapsidation 
and release during entry proved extremely sensitive to even subtle molecular 
disturbances (reviewed in (50)). In this study we describe the mechanism-of-action of 
ST-148, a recently identified small-molecule inhibitor that binds to and induces 
resistance in DV capsid (13). By using a combination of full-length reporter viruses and 
DVTCP, we identified two distinct inhibitory effects: impaired DV entry and reduced 
production of infectious virus particles. Based on BRET assays, in silico docking and 
MD simulations, we propose that these antiviral effects might be the result of stabilized 
capsid self-interaction. 
With respect to inhibition of virus entry, the lack of virucidal effects and the observed 
specific inhibitory effects of ST-148 on virus entry up to 30 minutes post-infection point 
towards a block in viral RNA uncoating. Although no detailed kinetics of nucleocapsid 
disassembly have been reported to date, earlier studies suggested that DV is 
internalized within 30 min after inoculation (51, 52). While our data do not demonstrate 
inhibition of the uncoating process, the observed increase of capsid self-interaction 
makes this assumption plausible. Nevertheless, additional experiments are required to 
͵͵ 
directly demonstrate that viral RNA release is blocked at the nucleocapsid 
disassembly/RNA uncoating step. 
In addition to impaired entry, ST-148 also reduced virus production. This might occur at 
the level of particle assembly or their release, but is likely not due to alteration of 
specific infectivity of DV particles, as suggested by the concomitant reduction in both 
the released infectivity and the secreted viral RNA. Consistent with this result, we note 
that in spite of the overall reduction of electron-dense virus particles found within DV-
infected cells upon ST-148 treatment, particle morphology appeared unaltered. 
Interestingly, these particles accumulated in larger numbers within ER stacks. 
Whether this phenomenon is a consequence of altered nucleocapsid assembly or 
results from disturbed intracellular transport of assembled virions remains to be 
determined. In any case, the observed redistribution of capsid from the cytosol to the 
nucleoli in ST-148-treated cells might contribute to the interference with virus production 
by reducing the amount of capsid protein available for assembly. Although lower 
cytoplasmic capsid levels were observed also for the DVS34L mutant, its ability to traffic 
in and out of the nucleus is likely not compromised, or is sufficient to support virion 
morphogenesis. Conversely, in case of the WT capsid, the ST-148-induced nuclear 
retention correlated with an alteration of the protein/protein complexes solubility, which 
might account for the observed reduction in virus production. 
The proposed mechanism-of-action for both the early and late stage inhibition of 
ST-148 involves a direct effect on higher-order structures of DV capsid. This 
assumption is supported by the significant and dose-dependent increase in capsid self-
interaction as observed by BRET. Since we used conditions of BRETmax, our results 
͵Ͷ 
suggest that the compound induces the formation of higher order oligomeric capsid 
species or stabilizes further pre-existing capsid dimers. This effect was specific for the 
wildtype capsid protein and not due to pleiotropic effects caused by the compound, 
because the interaction profile of the ST-148-resistant mutant was unaltered.  
By using MD, we generated a model of a capsid tetramer in complex with ST-148. 
Obtained results confirmed that ST-148 stabilizes capsid self-interaction. Thus, ST-148 
can be classified as a direct protein-protein interaction (PPI) stabilizer, establishing 
hydrophobic and electrostatic interactions in a cleft in-between the capsid dimers. As 
shown by our MD simulations, ST-148 retains the ability to bind the S34L-containing 
tetramer, but in a less stable conformation and involving only one dimer. Molecular 
modeling data are therefore in agreement with the previously observed binding of ST-
148 to both the wildtype and the S34L-containing capsid protein (13). Furthermore, our 
in silico results clarify the role of S34L mutation in drug resistance, as the steric 
hindrance of leucine at position 34 impedes a stable binding of the compound to the 
tetrameric capsid protein complex. 
Drug-induced modulation of capsid protein self-interactions is not unique to DV 
and has been described as an applicable strategy for several other enveloped viruses. 
For instance, in case of Hepatitis B virus several inhibitors targeting the core protein 
have been reported, and at least two classes of HBV assembly effectors, the 
heteroaryldihydropyrimidines (HAPs) and phenylpropenamides, have been extensively 
characterized (53, 54, 55, 56). For the HAPs, elegant work from Zlotnick and colleagues 
demonstrated that these compounds can increase the kinetics of assembly and 
strengthen dimer-dimer association to stabilize capsids (57, 58). Comparable to HAPs, 
͵ͷ 
certain phenylpropenamides accelerate assembly and stabilize capsids and some of 
these compounds, such as AT-130, were shown to block viral RNA packaging without 
altering the geometry of nucleocapsids; they still formed, but were devoid of nucleic 
acids (59, 60). Interestingly, molecules belonging to either class were shown to bind to 
partially overlapping sites of the HBV core protein. 
In case of HIV, different series of capsid inhibitors have been identified. For instance, 
the benzodiazepine (BD) and the benzimidazole (BM) series were reported to inhibit 
virion release or prevent virus maturation, respectively (61, 62). In case of the BD 
series, molecular studies, complemented by nuclear magnetic resonance and 
crystallography approaches, have shown that compounds from this class inhibited HIV 
particle release by blocking assembly of immature capsids (63). Conversely, molecules 
of the BM series did not affect virus budding, but prevented capsid maturation. Similar 
to HBV, these two compound series induced different biological phenotypes, although 
they both shared the same binding site within the N-terminal domain of the HIV capsid 
protein (64).  
We note that Blair and colleagues characterized another series of HIV-1 capsid-
targeting compounds interfering with both viral uncoating and formation of infectious 
particles (65). Similar to ST-148, these effects appeared to be mediated by the direct 
binding of the compound to HIV-1 capsid protein, increasing the rate of capsid protein 
multimerization. Similar to the study of Blair et al., a recent study reported the 
identification of a novel class of HIV-1 capsid inhibitors accelerating HIV capsid-
nucleocapsid assembly and stabilizing preassembled capsid-nucleocapsid tubes 
͵͸ 
against dissociation (66). These reports strengthen the concept of potent inhibition of 
viral replication via stabilization of the viral capsid. 
Comparable to what has been reported for the anti-HBV HAPs, we hypothesize that the 
late stage inhibitory effect of ST-148 on DV might result from stabilization of capsid 
protein inter-dimer association, which might reduce capsid plasticity and its ability to 
package viral RNA. Additionally, ST-148 seems to share selected features with the anti-
HIV pyrrolopyrazolones, exerting anti-viral activity on the early steps of the viral 
replication cycle presumably by stabilizing pre-existing capsid quaternary structures. 
However, the mechanism by which these HIV inhibitors stabilize capsid complexes is 
uncertain, because the inhibitor binding site does not reside within an inter- or 
intrahexameric capsid interface stabilizing the capsid lattice, while in case of ST-148, 
the putative binding site was identified in between two DV capsid dimers.  
A growing list of studies supports the notion that the multifunctional role of viral capsid 
protein, involving different protein conformations and interactions with different protein 
surfaces and host factors, represent a target that can be exploited for the development 
of potent inhibitors. Our work supports this hypothesis and argues that inhibitors 
targeting viral capsid proteins might also be applicable to flaviviruses. Given the lack of 
approved DV-specific antiviral drugs, this target should be further investigated, ideally to 
design combination therapies with a high genetic resistance barrier. 
In conclusion, we determined the mode-of-action of a DV capsid inhibitor that affects 
both entry and assembly/release of infectious virus particles. The antiviral effect 
appears to be mediated by enhanced capsid protein interaction, eventually inducing 
structural rigidity and/or steric hindrance during nucleocapsid formation, respectively. 
͵͹ 
These results, together with the first description of a robust BRET-based assay to 
measure capsid self-interaction in live cells, might serve as starting point for 
optimization of more effective therapeutics targeting simultaneously early and late 
stages of the DV life cycle. 
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Figure legends 
Figure 1: Schematic representation of constructs used in this study and antiviral 
potency of ST-148. (A) Schematic representation of genomic and subgenomic 
constructs. The DV2 full-length genome is shown at the top (DV). The 5 and 3 NTRs 
are depicted with their putative secondary structures. Polyprotein cleavage products are 
separated by vertical lines and labeled as specified in the introduction. The DVR2A is 
derived from the DV2 full-length genome by insertion of a Renilla luciferase coding 
sequence preceded by the capsid cyclization sequence (CAE) and followed by a Tosea 
asigna virus 2A cleavage site. The middle panel depicts the constructs used for 
production of trans-complemented DV particles (DVTCP). sgDVR2A is a subgenomic 
reporter replicon that is packaged into virus-like particles by the capsid and 
prM/envelope proteins transiently expressed in trans via two different lentiviruses (pWPI 
capsid-BLR and pWPI prME-Puro, respectively). All constructs are derived from the 
DVs2 16681 isolate (17). The right panel depicts the constructs used for BRET 
experiments. YFP and Renilla luciferase proteins were N-terminally fused to either 
capsid or NS4A of DV2 (strain 16681). (B) Structure of ST-148. (C) Anti-viral potency of 
ST-148. Huh7 cells were infected with 0.1 MOI of DV or the DVR2A reporter virus, 
containing or not the resistance mutation S34L, for 60 min at 37°C in the presence of 
various concentrations of the compound. After removal of the inoculum and several 
times washing with PBS, cells were incubated with fresh medium containing various 
concentrations of ST-148 or DMSO. After 48h, virus amounts released into the 
ͷͳ 
supernatant were determined by PFU assay with VeroE6 cells. Data represent 
averages and error ranges of two independent experiments. 
Figure 2: ST-148 does not affect viral RNA replication but reduces production of 
infectious DV particles. (A) No effect of ST-148 on replication kinetics of the DVR2A 
reporter virus. Huh7 cells were infected with 0.1 or 1 MOI of DVR2A for 4h at 37°C, 
washed with PBS and incubated with fresh medium containing 5 µM of ST-148 or 
DMSO. At indicated time points after infection luciferase activity was measured in the 
lysates. Note that error bars are not well visible due to the size of graph. (B) Reduction 
of virus production by ST-148. Supernatants of infected cells treated with 5 µM ST-148 
were harvested 72h post-infection and used to infect naïve Huh7 cells. After 48h, cells 
were harvested and luciferase activity was measured as described above. (C) 
Comparison of replication kinetics of DVR2A and DVR2AS34L in presence or absence of 
ST-148. Huh7 cells were electroporated with 10 µg of capped in vitro transcripts of 
wildtype (WT) DVR2A or DVR2AS34L (S34L), and 4h later, 5 µM of ST-148 or DMSO 
was added to the medium. At time points specified in the bottom, luciferase activity was 
measured as described above. (D) Inhibition of virus production by DVR2A and 
DVR2AS34L transfected cells upon ST-148 treatment. Supernatants of transfected and 
ST-148-treated cells were harvested 72h post-infection and used to infect naïve Huh7 
cells. After 48h, cells were harvested and luciferase activity measured as described 
above. Data in (A-D) represent average and standard deviation of three independent 
experiments (*** p<0.001 * p<0.05). 
ͷʹ 
Figure 3: Inhibition of the release of infectious DV particles by ST-148 as revealed 
by single-cycle experiments. (A) Production of infectious extracellular DV upon ST-
148 treatment and (B) quantification of released viral RNA. Huh7 cells were infected 
with 1 MOI of DVR2A for 4h at 37°C, washed with PBS and incubated with fresh 
medium containing DMSO or given concentrations of ST-148. After 48h, clarified 
supernatants were used for TCID50 assay to quantify infectivity titers or two-step qRT-
PCR for quantification of viral RNA amounts released into the supernatant. Data were 
analyzed using one-way ANOVA and Dunnetts post-hoc test (**p<0.01; ***p<0.001). 
(C) Determination of infection efficiency. Cells were infected with DV or DVS34L and 48h
later were fixed and analyzed by immunofluorescence using a DV E-specific antibody. 
Nuclear DNA was stained with DAPI. Numbers in the lower right of the panels refer to 
the percentage of infected cells (mean of at least 1,500 cells ± standard deviation). (D, 
E) Effect of ST-148 on single-round DV particle release. Huh7 cells were infected with
DV or DVS34L for 48h, washed extensively with PBS and incubated 12h with medium 
containing 0.1% DMSO, 1g/ml brefeldin A (BFA) or 10 µM ST-148. Released infectivity 
and viral RNA were quantified by TCID50 assay and qRT-PCR, respectively. Results 
represent mean and standard deviation of at least 3 independent experiments. (ns= 
non-significant; * p<0.05; ***p<0.001). 
Figure 4: ST-148 additionally inhibits DV particle entry. (A) Schematic 
representation of the system used to produce trans-complemented DV particles 
(DVTCP). 293T cells were electroporated with 10 µg of capped in vitro transcripts of the 
subgenomic replicon sgDVR2A [1]. The next day, cells were transiently transduced with 
ͷ͵ 
lentiviruses expressing the structural proteins capsid (wildtype or containing the ST-148 
resistance mutation S34L) and prM-E [2]. Replicating viral RNA is packaged in trans [3] 
giving rise to DVTCP that are released into the culture supernatant and harvested four to 
six days after transduction [4]. (B) Effect of ST-148 on entry of DVTCP. Huh7 cells were 
infected with DVTCP (wildtype (WT) or the S34L mutant), for 90 min at 37°C. The 
inoculum was removed and fresh medium was added. At time points specified in the 
bottom of the graph, medium was replaced by medium containing 10 µM ST-148 or 
0.1% DMSO. In one case (-120 min), cells were pre-treated with ST-148 for 2h prior to 
infection. Cells were harvested 48h post infection and luciferase activities in the lysates 
were measured. (C) No virucidal effect of ST-148. Stocks of DV wildtype or DVS34L were 
incubated at 37°C for 1h with 10 µM ST-148 or 0.1% DMSO and used to determine 
infectivity titers by limiting dilution assay (TCID50). Data represent average and standard 
deviation of three independent experiments (ns= non-significant; * p<0.05; ** p<0.001). 
Figure 5: Effect of ST-148 on subcellular localization of viral RNA and protein and 
accumulation of DV particles in ER stacks. (A) Colocalization of capsid with dsRNA 
and LDs in ST-148 treated cells. Huh7 cells were infected with 1 MOI of DV wildtype 
and 4h later, DMSO or 10 µM of ST-148 was added to the medium. After 48h cells were 
fixed with 4% PFA in 4%sucrose. To visualize cytosolic LD-associated capsid protein, 
cells were permeabilized with 0.1% TritonX-100, and incubated with a rabbit polyclonal 
anti-capsid antibody, mouse anti-dsRNA antibody and Bodipy-488 (to detect LDs). 
Scale bars represent 10 µm. (B, C) Impact of ST-148 on LD size and number, 
respectively. The mean area and number of LDs per cell has been calculated by using 
ͷͶ 
the Fiji plug-in of ImageJ. Each dataset represents average and standard deviation of at 
least 500 cells per condition (* p<0.05). (D) Accumulation of DV particles in ER stacks 
upon ST-148 treatment. Huh7 cells were infected with DV wildtype (WT) or the DVS34L
mutant (S34L) with a MOI of 3. Four hours after infection the inoculum was removed 
and cells were incubated for 44h in presence of 10 µM ST-148 or DMSO. Cells were 
fixed, processed and analyzed by transmission electron microscopy as described in 
materials and methods. The areas boxed in the left panels are shown at higher 
magnification on the right. Scale bars in each panel represent 200 nm. (E) 
Quantification of intracellular DV particle distribution. The number of virions present in 
ER stacks were quantified and assigned to 3 categories according to the number of 
virions per stack. Each column represents the mean of at least 1,000 virions from at 
least 15 infected cells per condition. 
Figure 6: ST-148 induces accumulation of capsid protein in nuclear insoluble 
aggregates. (A) Intracellular distribution of capsid protein upon ST-148 treatment. Huh7 
cells were infected with 1 MOI of DV or DVS34L and 4h later, DMSO or 10 µM of ST-148 
was added to the medium. After 48h, cells were fixed with 4% paraformaldehyde, 
permeabilized with 0.5% TritonX-100 and immune-stained for capsid with a mouse-
monoclonal antibody. Scale bars represent 20 µm. (B) Image-based quantification of 
intracellular distribution of capsid protein. The extent of nuclear localization of capsid 
was determined by quantifying capsid-specific signals detected in the nucleus (N) and 
the cytoplasm (C), respectively, and calculating the ratio of mean fluorescence in these 
two compartments. Results represent the mean ± SEM (n50). Data were analyzed 
ͷͷ 
using one-way ANOVA with Tukeys post-hoc test (*** p<0.001; ns, non-significant). (C) 
Subcellular fractionation of DV proteins. Huh7 cells were infected with 1 MOI of DV or 
DVS34L and 4h later, cells were treated with DMSO or 10 µM ST-148. Intracellular 
distribution of capsid in soluble cytosolic (Cyt), membrane-associated (Membr), nuclear 
(Nuc) and post-nuclear insoluble (Post-Nuc) fractions was evaluated by Western blot. 
GAPDH, ATP5B, Lamin A/C and Vimentin served as specificity controls for the various 
fractions. Numbers below each lane refer to the relative amounts of C proteins as 
determined by densitometry. After subtraction of the background, capsid-specific signals 
in each fraction were normalized to the corresponding input and expressed as fold of 
total signal in the four fractions. Numbers in the left refer to the positions of molecular 
weight standards. One result of two independent experiments is shown. 
Figure 7: ST-148 increases DV capsid protein self-interaction. (A) Self-interaction 
kinetics of WT and S43L capsid as determined by BRET. Donor-Saturation Assays 
were performed in live 293T cells co-transfected with increasing amount of YFP-tagged 
and a constant amount of Rluc-tagged plasmids encoding for wildtype (WT) or mutant 
(S34L) capsid or NS4A, which served as negative control. Forty-eight hours later, 
energy transfer was induced by the addition of the Renilla luciferase substrate 
coelenterazine H. The X-axis shows the ratio between the normalized fluorescence of 
the acceptor (netYFP) measured before coelenterazine addition, and the luminescence 
of the donor. BRET50 values (ratio of netYFP/Renilla at which 50% of maximal BRET is 
occurring), which reflect the relative affinity of the acceptor protein for the donor protein, 
are given in the top right of the panel. Shown curves represent the means ± standard 
ͷ͸ 
deviations of results from one representative experiment carried out in triplicate. The 
curves were fitted using a nonlinear regression equation, in which a single binding site 
was assumed. (B) Effect of ST-148 on capsid self-interaction. 293T cells were 
transfected with 1 µg of YFP-capsid and 20 ng of Rluc-capsid (WT and S34L). Prior to 
transfection, different concentrations of ST-148 or DMSO were added to the medium 
and 48h later BRET was measured (*** p<0.001 * p<0.01). 
Figure 8: Docking model of ST-148 and DV capsid and possible stabilization of 
inter-dimer capsid protein interaction. (A) Sequence comparison of capsid amino 
acid sequences of DV serotypes 1-4 and selected flaviviruses. In red the position of the 
serine 34 is highlighted. Sequence alignment was carried out using the ClustalW 
algorithm available at the Uniprot webserver, on the following isolates: DV-2 
(Thailand/16681-PDK53), DV-1 (Brazil/97-11/1997), DV-3 (Martinique/1243/1999), DV-4 
(Thailand/0348/1991), West-Nile virus - WNV (H442), Yellow Fever virus - YFV (Ivory 
Coast/1999), Japanese Encephalitis virus - JEV (SA-14), Kunjin virus - KUNV 
(MRM61C), St.Louis Encephalitis virus - SLEV (MS1-7). UniprotKB accession numbers 
are given in the materials and methods section. (B) Results from molecular dynamics 
(MD) simulations. Stable conformations of the wildtype capsid tetramer in absence (left
panel) or presence (right panel) of ST-148. Capsid dimers are represented in blue and 
orange, with each monomer given in different shades of the same color. ST-148 is 
shown with green sticks and the serine residue at position 34 is represented with the 
Corey-Pauling-Koltun (CPK) model. Movies of the MD simulations are given in the 
supplementary materials. (C) Results of superimposition of the MD simulation of the 
ͷ͹ 
wildtype C tetramer in absence (red ribbon) or presence (blue ribbon) of ST-148 are 
presented on the left panel. ST-148 is shown in green with the CPK model. A closer 
view of the same superimposition is presented in the right panel with the same color 
code. The dashed arrows indicate the structural rearrangements, which occur to 2 and 
3 helices upon ST-148 binding and allow accommodating the ligand. (D, E) Close view 
of the docking pose of ST-148. (D) Wildtype capsid dimer-dimer interface complexed 
with ST-148; (E) same interface as in (D) with the serine residue superimposed to 
Leu34. The dashed circle highlights the steric hindrance induced by the leucine residue 
at position 34, thus clarifying how the mutation impedes this binding pose. In both 
panels one dimer is depicted in light blue, while the other capsid dimer is in red in case 
of the wildtype, or in yellow in case of the S34L resistance mutant. Protein residues are 
displayed as lines, while Ser34 and Leu34 are drawn to attention with stick 
representation. 
TABLE 1: Antiviral activity of ST-148 against DV 16681-based viruses. 
Virus EC50
a
(µM)
DV2 0.052±0.016 
DVR2A 0.037±0.028 
DVS34L 11.79±2.34 
DVR2AS34L 11.14±3.27 
a Cells were infected with given viruses at a MOI of 0.1 and treated with ST-148. Culture 
medium was collected 48h post infection and virus titers were determined by plaque 
ͷͺ 
assay (Huh7 cells, CC50>100µM as determined in (13)). Data represent averages and 
error ranges of two independent experiments.  








